These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 31631026)

  • 21. Histone H3.3K27M Represses
    Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
    Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
    Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
    Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
    Grasso CS; Tang Y; Truffaux N; Berlow NE; Liu L; Debily MA; Quist MJ; Davis LE; Huang EC; Woo PJ; Ponnuswami A; Chen S; Johung TB; Sun W; Kogiso M; Du Y; Qi L; Huang Y; Hütt-Cabezas M; Warren KE; Le Dret L; Meltzer PS; Mao H; Quezado M; van Vuurden DG; Abraham J; Fouladi M; Svalina MN; Wang N; Hawkins C; Nazarian J; Alonso MM; Raabe EH; Hulleman E; Spellman PT; Li XN; Keller C; Pal R; Grill J; Monje M
    Nat Med; 2015 Jun; 21(6):555-9. PubMed ID: 25939062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
    Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soft drug inhibitors for the epigenetic targets lysine-specific demethylase 1 and histone deacetylases.
    Seitz J; Auth M; Prinz T; Hau M; Tzortzoglou P; Schulz-Fincke J; Schmidtkunz K; Baniahmad AA; Willmann D; Metzger E; Hein L; Preissl S; Schüle R; Jung M
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400450. PubMed ID: 39004853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential.
    Kfoury-Beaumont N; Prakasam R; Pondugula S; Lagas JS; Matkovich S; Gontarz P; Yang L; Yano H; Kim AH; Rubin JB; Kroll KL
    BMC Biol; 2022 May; 20(1):124. PubMed ID: 35637482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
    Larson JD; Kasper LH; Paugh BS; Jin H; Wu G; Kwon CH; Fan Y; Shaw TI; Silveira AB; Qu C; Xu R; Zhu X; Zhang J; Russell HR; Peters JL; Finkelstein D; Xu B; Lin T; Tinkle CL; Patay Z; Onar-Thomas A; Pounds SB; McKinnon PJ; Ellison DW; Zhang J; Baker SJ
    Cancer Cell; 2019 Jan; 35(1):140-155.e7. PubMed ID: 30595505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
    Balakrishnan I; Danis E; Pierce A; Madhavan K; Wang D; Dahl N; Sanford B; Birks DK; Davidson N; Metselaar DS; Meel MH; Lemma R; Donson A; Vijmasi T; Katagi H; Sola I; Fosmire S; Alimova I; Steiner J; Gilani A; Hulleman E; Serkova NJ; Hashizume R; Hawkins C; Carcaboso AM; Gupta N; Monje M; Jabado N; Jones K; Foreman N; Green A; Vibhakar R; Venkataraman S
    Cell Rep; 2020 Oct; 33(3):108286. PubMed ID: 33086074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Mendez FM; Núñez FJ; Garcia-Fabiani MB; Haase S; Carney S; Gauss JC; Becher OJ; Lowenstein PR; Castro MG
    Neuro Oncol; 2020 Feb; 22(2):195-206. PubMed ID: 32078691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic Treatment Options in Urothelial Carcinoma.
    Pinkerneil M; Hoffmann MJ; Niegisch G
    Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
    He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H
    Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.
    Lewis NA; Klein RH; Kelly C; Yee J; Knoepfler PS
    Epigenetics Chromatin; 2022 May; 15(1):18. PubMed ID: 35590427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
    Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
    Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemotherapy in breast cancer.
    Yang Y; Huang W; Qiu R; Liu R; Zeng Y; Gao J; Zheng Y; Hou Y; Wang S; Yu W; Leng S; Feng D; Wang Y
    J Mol Cell Biol; 2018 Aug; 10(4):285-301. PubMed ID: 29741645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.